Ayla Ellison

1 day ago | fiercepharma.com | Ayla Ellison |Angus Liu |Gabrielle Masson |Zoey Becker

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The Top Line," Fierce reporters take you inside the action at ASCO 2025. Zoey Becker shares the story behind Johnson & Johnson’s dramatic “Breathtaking” campaign, staged on the 99th floor of Chicago’s Willis Tower.

1 week ago | fiercepharma.com | Ayla Ellison |Eric Sagonowsky |Kevin Dunleavy |Gabrielle Masson

Despite the long holiday weekend, news in biopharma never slows down. In this week’s episode of "The Top Line," the Fierce team breaks down some of the biggest stories from the past week. On the pharma side, Eric Sagonowsky and Kevin Dunleavy examine Big Pharma’s first-quarter 2025 performance. While most of the top 25 companies are still delivering strong sales growth despite emerging uncertainties in Washington, D.C., a few major players are starting to see a slowdown.

2 weeks ago | fiercehealthcare.com | Ayla Ellison |Heather Landi

AI is racing into healthcare, but most organizations are still stuck at the starting line. A new report from Bessemer Venture Partners, Bain & Company and Amazon Web Services offers a view of AI in healthcare, drawing on a survey of more than 400 leaders across payers, providers and pharma. The findings reveal a stark contrast: more than 80% of respondents believe AI will transform clinical decision-making in the coming years, yet only 30% of pilots make it to production.

3 weeks ago | fiercepharma.com | Ayla Ellison |Eric Sagonowsky |Kevin Dunleavy |Angus Liu

President Donald Trump put the pharmaceutical industry on notice early Monday with the signing of his "most favored nation" (MFN) executive order on drug prices. The order seeks to tie U.S. prices to significantly lower costs overseas. Many questions remain about how the measure will be implemented, and legal challenges are almost certain. To assess the seriousness of the threat, Fierce Pharma assembled a team of reporters and editors to break down the executive order and the industry’s response.

3 weeks ago | fiercehealthcare.com | Ayla Ellison |Paige Minemyer |Dave Muoio

The healthcare industry is preparing for significant regulatory change in the latter half of 2025, and much of the conversation on the first quarter earnings calls was about setting the tone for those complications. Tariffs, Medicaid cuts and the likely end of the enhanced ACA subsidies all have major implications for payers and providers, and industry behemoth UnitedHealth Group is headlining those trends with an unusual miss and the departure of its CEO, Andrew Witty.